|
Volumn 20, Issue 24, 2001, Pages 3807-3815
|
Analysis of recurrent failure times data: Should the baseline hazard be stratified?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTHRACYCLINE;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FLUDARABINE;
IMMUNOSTIMULATING AGENT;
PLACEBO;
PREDNISONE;
VINCRISTINE;
ADVERSE DRUG REACTION;
ARTICLE;
CHEMOTHERAPY;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL STUDY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COVARIANCE;
DATA ANALYSIS;
HUMAN;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
POISSON DISTRIBUTION;
RANDOMIZED CONTROLLED TRIAL;
RECURRENT INFECTION;
RHINITIS;
STATISTICAL ANALYSIS;
THEORY;
ADJUVANTS, IMMUNOLOGIC;
ADULT;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
DATA INTERPRETATION, STATISTICAL;
DISEASE-FREE SURVIVAL;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
MULTICENTER STUDIES;
NEOPLASM RECURRENCE, LOCAL;
PROPORTIONAL HAZARDS MODELS;
RANDOMIZED CONTROLLED TRIALS;
RHINITIS;
TREATMENT FAILURE;
VIDARABINE;
|
EID: 0035977406
PISSN: 02776715
EISSN: None
Source Type: Journal
DOI: 10.1002/sim.909 Document Type: Article |
Times cited : (16)
|
References (16)
|